Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 21, 2026, 9:25 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1009–1032 of 9,285 matching trials from the live ClinicalTrials.gov search.
Conditions
Geographic Atrophy
Interventions
NGM621
Biological
Lead sponsor
NGM Biopharmaceuticals, Inc
Industry
Eligibility
50 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
6
States / cities
Arcadia, California • Newport Beach, California • Melbourne, Florida + 3 more
Terminated Phase 1 Interventional Accepts healthy volunteers

Aerosolized and Intravenous Colistin in Healthy Adults

NCT01863719
Conditions
Pathogen Resistance, Pneumococcal Infection, Pneumonia
Interventions
Colistimethate sodium
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2017
U.S. locations
2
States / cities
Baltimore, Maryland • Cleveland, Ohio
Conditions
Tumor, Solid
Interventions
BDB001 (EIK1001), Atezolizumab
Drug
Lead sponsor
Eikon Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
5
States / cities
Los Angeles, California • Sarasota, Florida • Nashville, Tennessee + 1 more
Conditions
Relapsed/Refractory Multiple Myeloma
Interventions
agenT-797
Drug
Lead sponsor
MiNK Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
3
States / cities
Louisville, Kentucky • Boston, Massachusetts • Cincinnati, Ohio
Completed Phase 1 Interventional Accepts healthy volunteers

Safety of Sublingual dmLT for ETEC

NCT02052934
Conditions
Gastroenteritis Escherichia Coli
Interventions
Recombinant Double Mutant Heat-Labile Toxin LT(R192G/L211A) (dmLT) Oral enterotoxigenic Escherichia coli (ETEC) Vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Cincinnati, Ohio
Conditions
HIV Infections
Interventions
CCR5mAb004
Drug
Lead sponsor
Human Genome Sciences Inc.
Industry
Eligibility
18 Years to 64 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
7
States / cities
Los Angeles, California • San Francisco, California • Fort Lauderdale, Florida + 4 more
Conditions
Tuberculosis
Interventions
PA-824
Drug
Lead sponsor
Global Alliance for TB Drug Development
Other
Eligibility
19 Years to 50 Years · Male only
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
Madison, Wisconsin
Conditions
Recurrent Head and Neck Cancer
Interventions
Ad/PNP, Fludarabine Phosphate
Biological · Drug
Lead sponsor
GeoVax, Inc.
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
3
States / cities
Stanford, California • Atlanta, Georgia • Philadelphia, Pennsylvania
Conditions
Solid Neoplasms
Interventions
Dazostinag, Pembrolizumab, Platinum, 5-fluorouracil
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
248 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
26
States / cities
La Jolla, California • Los Angeles, California • Orange, California + 20 more
Conditions
Stroke
Interventions
Full-pressure ECP, Sham-pressure ECP
Device
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 85 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
3
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California
Not listed Phase 1 Interventional

Phase 1 Study of HBN-1

NCT04094857
Conditions
Cardiac Arrest
Interventions
HBN-1
Drug
Lead sponsor
Hibernaid, Inc
Industry
Eligibility
40 Years to 80 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
2
States / cities
Portland, Maine • Pittsburgh, Pennsylvania
Completed Phase 1 Interventional Accepts healthy volunteers

Drug Interaction Study of ASC42 With Atorvastatin

NCT05464628
Conditions
Healthy
Interventions
Atorvastatin, ASC42
Drug
Lead sponsor
Gannex Pharma Co., Ltd.
Industry
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
San Antonio, Texas
Conditions
Non Small Cell Lung Cancer, Colorectal Cancer, Pancreatic Cancer, Solid Tumor, Cancer, Cancer of Pancreas, Cancer of Colon
Interventions
HBI-2376
Drug
Lead sponsor
HUYABIO International, LLC.
Industry
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
11
States / cities
Duarte, California • Encinitas, California • Fullerton, California + 7 more
Conditions
Healthy
Interventions
PF 06260414 solid dose formulation, PF-06260414 nanosuspension
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
New Haven, Connecticut
Conditions
Advanced or Metastatic Solid Tumors, Triple Negative Breast Cancer (TNBC), HR+ Breast Cancer, Colon Cancer, Gastric Cancer, Hepatecellular Carcinoma, NSCLC (Advanced Non-small Cell Lung Cancer), Mesothelioma, Pancreatic Carcinoma Metastatic, Hormone Refractory Prostate Cancer, Soft Tissue Sarcomas
Interventions
SHY-ONC6
Drug
Lead sponsor
SHY Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
3
States / cities
Scottsdale, Arizona • Houston, Texas • San Antonio, Texas
Conditions
Tumors
Interventions
Lenvatinib, Midazolam
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
4
States / cities
Detroit, Michigan • The Bronx, New York • Philadelphia, Pennsylvania + 1 more
Conditions
Chronic Granulomatous Disease (CGD), X-Linked Chronic Granulomatous Disease
Interventions
Campath, Sirolimus, Base-edited hematopoietic stem and progenitor cells, Busulfan, Palifermin, Filgrastim, Plerixafor
Drug · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 75 Years · Male only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2032
U.S. locations
1
States / cities
Bethesda, Maryland
Completed Phase 1 Interventional Accepts healthy volunteers

Phase 1 Healthy Volunteer Burn Therapy Study

NCT06223009
Conditions
Burns
Interventions
cNP8, Placebo
Drug · Other
Lead sponsor
Neomatrix Therapeutics, Inc.
Other
Eligibility
18 Years to 65 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Saint Paul, Minnesota
Conditions
Metastatic Myxoid Liposarcoma, Metastatic Round Cell Liposarcoma, Metastatic Synovial Sarcoma, Recurrent Mycosis Fungoides and Sezary Syndrome, Refractory Mycosis Fungoides and Sezary Syndrome, Stage IB Mycosis Fungoides and Sezary Syndrome AJCC v7, Stage II Mycosis Fungoides and Sezary Syndrome AJCC v7, Stage IIA Mycosis Fungoides and Sezary Syndrome AJCC v7, Stage IIB Mycosis Fungoides and Sezary Syndrome AJCC v7, Stage III Mycosis Fungoides and Sezary Syndrome AJCC v7, Stage IIIA Mycosis Fungoides and Sezary Syndrome AJCC v7, Stage IIIB Mycosis Fungoides and Sezary Syndrome AJCC v7, Stage IV Mycosis Fungoides and Sezary Syndrome AJCC v7, Stage IVA Mycosis Fungoides and Sezary Syndrome AJCC v7, Stage IVB Mycosis Fungoides and Sezary Syndrome AJCC v7, Unresectable Synovial Sarcoma
Interventions
Interferon Gamma-1b, Laboratory Biomarker Analysis, Pembrolizumab
Biological · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
12 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
7
States / cities
Palo Alto, California • Miami, Florida • Boston, Massachusetts + 4 more
Conditions
Advanced Solid Tumors
Interventions
TP-3654
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
3
States / cities
Houston, Texas • Salt Lake City, Utah • Charlottesville, Virginia
Conditions
Solid Tumor, Adult
Interventions
KQB198, Osimertinib, Amivantamab
Drug
Lead sponsor
Kumquat Biosciences Inc.
Industry
Eligibility
18 Years and older
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
9
States / cities
Denver, Colorado • Orlando, Florida • Sarasota, Florida + 6 more
Conditions
Healthy
Interventions
azelaic acid pre foam formulation, Vehicle pre foam formulation, Water
Drug
Lead sponsor
LEO Pharma
Industry
Eligibility
18 Years to 65 Years
Enrollment
240 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Fargo, North Dakota
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Study of V132 in Healthy Older Participants (V132-001)

NCT07712575
Conditions
Healthy
Interventions
V132 Formulation 1, V132 Formulation 2, V132 Formulation 3, PREVNAR 20™, CAPVAXIVE™
Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
50 Years to 75 Years
Enrollment
280 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
10
States / cities
Anaheim, California • Hallandale, Florida • Hollywood, Florida + 7 more
Conditions
Absorption, Metabolism, Excretion
Interventions
Simufilam
Drug
Lead sponsor
Cassava Sciences, Inc.
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Madison, Wisconsin